First Allied Advisory Services’s AstraZeneca AZN Stock Holding History

First Allied Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1.91M	Buy	17,387 +10,760	+162%	+$1.2M	0.06%	306
2020 Q2	$701K	Buy	6,627 +1,205	+22%	+$124K	0.03%	550
2020 Q1	$484K	Sell	5,422 -882	-14%	-$83K	0.02%	602
2019 Q4	$627K	Sell	6,304 -194	-3%	-$18.3K	0.02%	631
2019 Q3	$576K	Buy	6,498 +1,426	+28%	+$124K	0.02%	637
2019 Q2	$419K	Buy	5,072 +193	+4%	+$15.1K	0.01%	740
2019 Q1	$389K	Sell	4,879 -3,481	-42%	-$274K	0.01%	756
2018 Q4	$633K	Sell	8,360 -894	-10%	-$69.8K	0.03%	538
2018 Q3	$739K	Sell	9,254 -853	-8%	-$64.5K	0.03%	569
2018 Q2	$714K	Sell	10,107 -673	-6%	-$48.4K	0.03%	556
2018 Q1	$752K	Sell	10,780 -1,143	-10%	-$79.2K	0.03%	534
2017 Q4	$825K	Buy	11,923 +847	+8%	+$57.1K	0.03%	498
2017 Q3	$750K	Buy	11,076 +1,363	+14%	+$86.1K	0.03%	489
2017 Q2	$663K	Sell	9,713 -480	-5%	-$31.3K	0.03%	532
2017 Q1	$666K	Buy	10,193 +2,028	+25%	+$118K	0.03%	497
2016 Q4	$446K	Sell	8,165 -993	-11%	-$56.4K	0.02%	623
2016 Q3	$602K	Buy	9,158 +3,403	+59%	+$222K	0.03%	504
2016 Q2	$343K	Sell	5,755 -1,283	-18%	-$74.5K	0.02%	690
2016 Q1	$397K	Sell	7,038 -215	-3%	-$12.9K	0.02%	631
2015 Q4	$488K	Buy	7,253 +312	+4%	+$20.5K	0.03%	586
2015 Q3	$443K	Buy	6,941 +195	+3%	+$12.8K	0.02%	593
2015 Q2	$430K	Buy	6,746 +2,463	+58%	+$169K	0.02%	667
2015 Q1	$292K	Sell	4,283 -1,309	-23%	-$91K	0.02%	791
2014 Q4	$392K	Buy	5,592 +800	+17%	+$57.3K	0.03%	615
2014 Q3	$342K	Buy	+4,792	New	+$351K	0.03%	669
2014 Q2	–	Sell	-5,737	Closed	-$369K	–	1006
2014 Q1	$369K	Sell	5,737 -38,023	-87%	-$2.46M	0.03%	629
2013 Q4	$2.62M	Sell	43,760 -49,668	-53%	-$2.7M	0.21%	139
2013 Q3	$4.89M	Buy	93,428 +32,382	+53%	+$1.63M	0.28%	103
2013 Q2	$2.89M	Buy	+61,046	New	+$3.11M	0.23%	129

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

First Allied Advisory Services's AZN Position: Q3 2020 in Review

First Allied Advisory Services increased its AstraZeneca (AZN) stake by 162% in Q3 2020, buying an estimated $1.2M and bringing the position to 17,387 shares worth $1.91M. The position accounts for 0.06% of the portfolio, ranked #306.

First Allied Advisory Services first reported a position in AZN in Q2 2013 and has held it in 29 quarters since. The position peaked at $4.89M in Q3 2013. 723 funds tracked by Wall St. Rank hold AZN as of Q3 2020.

First Allied Advisory Services held 17,387 shares of AstraZeneca worth $1.91M as of Q3 2020.
First Allied Advisory Services bought 10,760 AstraZeneca shares in Q3 2020, an estimated $1.2M.
AstraZeneca made up 0.06% of First Allied Advisory Services's portfolio in Q3 2020, its #306 holding.
First Allied Advisory Services first reported a position in AstraZeneca in Q2 2013 and has held it in 29 quarters since.
First Allied Advisory Services's AstraZeneca position peaked at $4.89M in Q3 2013.
723 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.